Outcome of patients with relapsed or progressive Ewing sarcoma enrolled on cooperative group phase 2 clinical trials: A report from the Children's Oncology Group

被引：12
|
作者：
Collier, Anderson B., III [1 ]
Krailo, Mark D. [2 ]
Dang, Ha M. [2 ]
DuBois, Steven G. [3 ,4 ]
Hawkins, Douglas S. [5 ]
Bernstein, Mark L. [6 ]
Bomgaars, Lisa R. [7 ]
Reed, Damon R. [8 ,9 ,10 ]
Gorlick, Richard G. [11 ]
Janeway, Katherine A. [3 ,4 ]
机构：
[1] Univ Mississippi, Dept Pediat, Med Ctr, 2500 North Sate St, Jackson, MS 38219 USA
[2] Univ Southern Calif, Dept Prevent Med, Los Angeles, CA 90007 USA
[3] Dana Farber Boston Childrens Canc & Blood Disorde, Boston, MA USA
[4] Harvard Med Sch, Boston, MA 02115 USA
[5] Seattle Childrens Hosp, Dept Pediat, Seattle, WA USA
[6] Dalhousie Univ, IWK Hlth Ctr, Port Williams, NS, Canada
[7] Baylor Coll Med, Dept Pediat, Dan L Duncan Comprehens Canc Ctr, Houston, TX 77030 USA
[8] Johns Hopkins All Childrens Hosp, Canc Ctr, St Petersburg, FL USA
[9] Johns Hopkins All Childrens Hosp, Blood Disorders Inst, St Petersburg, FL USA
[10] H Lee Moffitt Canc Ctr & Res Inst, Dept Individualized Canc Management, Tampa, FL USA
[11] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
PEDIATRIC BLOOD & CANCER | 2021年 / 68卷 / 12期
关键词：
event-free survival; Ewing sarcoma; objective response; outcome; phase; 2; trials; relapsed; REFRACTORY SOLID TUMORS; II TRIAL; CHEMOTHERAPY; CRITERIA;
D O I：
10.1002/pbc.29333
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
SevenChildren's Oncology Group phase 2 trials for patients with relapsed/progressive solid tumors were analyzed to estimate the event-free survival (EFS) for relapsed/progressive Ewing sarcoma. One hundred twenty-eight Ewing sarcoma patients were enrolled and 124 events occurred. The 6-month EFS was 12.7%, demonstrating the poor outcome of these patients. Only docetaxel achieved its protocol-specified radiographic response rate for activity; however, the EFS for docetaxel was similar to other agents, indicating that a higher radiographic response rate may not translate into superior disease control. This EFS benchmark could be utilized as an additional endpoint in trials for recurrent Ewing sarcoma.
引用
收藏
页数：5
相关论文
共 50 条
  • [41] Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children’s Oncology Group
    David S. Shulman
    Kelly Klega
    Alma Imamovic-Tuco
    Andrea Clapp
    Anwesha Nag
    Aaron R. Thorner
    Eliezer Van Allen
    Gavin Ha
    Stephen L. Lessnick
    Richard Gorlick
    Katherine A. Janeway
    Patrick J. Leavey
    Leo Mascarenhas
    Wendy B. London
    Kieuhoa T. Vo
    Kimberly Stegmaier
    David Hall
    Mark D. Krailo
    Donald A. Barkauskas
    Steven G. DuBois
    Brian D. Crompton
    British Journal of Cancer, 2018, 119 : 615 - 621
  • [42] Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group
    Shulman, David S.
    Klega, Kelly
    Imamovic-Tuco, Alma
    Clapp, Andrea
    Nag, Anwesha
    Thorner, Aaron R.
    Van Allen, Eliezer
    Ha, Gavin
    Lessnick, Stephen L.
    Gorlick, Richard
    Janeway, Katherine A.
    Leavey, Patrick J.
    Mascarenhas, Leo
    London, Wendy B.
    Vo, Kieuhoa T.
    Stegmaier, Kimberly
    Hall, David
    Krailo, Mark D.
    Barkauskas, Donald A.
    DuBois, Steven G.
    Crompton, Brian D.
    BRITISH JOURNAL OF CANCER, 2018, 119 (05) : 615 - 621
  • [43] Importance of review for cooperative group cytogenetic studies, a report from the Children's Oncology Group (COG)
    Heerema, NA
    Sanger, W
    Hirsch, B
    Magenis, ME
    McGavran, L
    Patil, S
    Rao, K
    Roulston, D
    CYTOGENETIC AND GENOME RESEARCH, 2004, 106 (01) : 136 - 136
  • [44] Predicting low accrual in the Clinical Trials Cooperative Group Program's phase II/III oncology trials
    Bennette, Caroline Savage
    Ramsey, Scott David
    McDermott, Cara L.
    Carlson, Josh John
    Basu, Anirban
    Veenstra, David L.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [45] The Impact of Chemotherapy Shortages on COG and Local Clinical Trials: A Report From the Children's Oncology Group
    Salazar, Elizabeth G.
    Bernhardt, M. Brooke
    Li, Yimei
    Aplenc, Richard
    Adamson, Peter C.
    PEDIATRIC BLOOD & CANCER, 2015, 62 (06) : 940 - 944
  • [46] MENTORING IN PEDIATRIC ONCOLOGY CLINICAL TRIALS: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP (COG) YOUNG INVESTIGATORS COMMITTEE
    Levy, Adam
    Gow, Kenneth
    Kim, Grace
    Maloney, Kelly
    PEDIATRIC BLOOD & CANCER, 2010, 54 (06) : 820 - 821
  • [47] Adverse prognostic impact of the loss of STAG2 protein expression in patients with newly diagnosed localised Ewing sarcoma: A report from the Children's Oncology Group
    Shulman, David S.
    Chen, Sonja
    Hall, David
    Nag, Anwesha
    Thorner, Aaron R.
    Lessnick, Stephen L.
    Stegmaier, Kimberly
    Janeway, Katherine A.
    DuBois, Steven G.
    Krailo, Mark D.
    Barkauskas, Donald A.
    Church, Alanna J.
    Crompton, Brian D.
    BRITISH JOURNAL OF CANCER, 2022, 127 (12) : 2220 - 2226
  • [48] Tumoral TP53 and/or CDKN2A Alterations Are Not Reliable Prognostic Biomarkers in Patients With Localized Ewing Sarcoma: A Report From the Children's Oncology Group
    Lerman, Daniel M.
    Monument, Michael J.
    McIlvaine, Elizabeth
    Liu, Xiao-qiong
    Huang, Dali
    Monovich, Laura
    Beeler, Natalie
    Gorlick, Richard G.
    Marina, Neyssa M.
    Womer, Richard B.
    Bridge, Julia A.
    Krailo, Mark D.
    Randall, R. Lor
    Lessnick, Stephen L.
    PEDIATRIC BLOOD & CANCER, 2015, 62 (05) : 759 - 765
  • [49] Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi-modality therapy: A report from the Children's Oncology Group
    Leavey, Patrick J.
    Mascarenhas, Leo
    Marina, Neyssa
    Chen, Zhengjia
    Krailo, Mark
    Miser, James
    Brown, Ken
    Tarbell, Nancy
    Bernstein, Mark L.
    Granowetter, Linda
    Gebhardt, Mark
    Grier, Holcombe E.
    PEDIATRIC BLOOD & CANCER, 2008, 51 (03) : 334 - 338
  • [50] Adverse prognostic impact of the loss of STAG2 protein expression in patients with newly diagnosed localised Ewing sarcoma: A report from the Children’s Oncology Group
    David S. Shulman
    Sonja Chen
    David Hall
    Anwesha Nag
    Aaron R. Thorner
    Stephen L. Lessnick
    Kimberly Stegmaier
    Katherine A. Janeway
    Steven G. DuBois
    Mark D. Krailo
    Donald A. Barkauskas
    Alanna J. Church
    Brian D. Crompton
    British Journal of Cancer, 2022, 127 : 2220 - 2226
12345